Recombinant PDCD1 (Nivolumab Biosimilar) anticorps

N° du produit ABIN7200667

Cet anticorps anti-PDCD1 (Nivolumab Biosimilar) Monoclonal Humanized (Clone 5C4-B8) (ABIN7200667) détecte spécifiquement PDCD1 (Nivolumab Biosimilar) dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant PDCD1 (Nivolumab Biosimilar) anticorps (ABIN7200667)

Antigène: PDCD1 (Nivolumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp PDCD1 (Nivolumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Clone: 5C4-B8

Détail du produit anti-PDCD1 (Nivolumab Biosimilar) anticorps

Fonction: Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody

Specificité: The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Attributs du produit: What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.

Isotype: IgG4

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Stock: 4°C,-20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur PDCD1 (Nivolumab Biosimilar)

Antigène: PDCD1 (Nivolumab Biosimilar)

Autre désignation: Nivolumab Biosimilar

Classe de substances: Biosimilar